The actual standardized mortality rate for pancreas malignant neoplasms stood at 16.0 male deaths per 100,000 men in 2023. The forecast from 2024 to 2028 predicts a stable rate of 16.1. This shows negligible year-on-year variation, underscoring a consistent trend with no apparent decrease or increase in mortality rates over the five-year period. The CAGR over this period remains effectively at zero, indicating a plateau in the rates, suggesting neither improvement nor deterioration.
Future trends to watch for include potential advancements in early detection and treatment methods, which could influence this stability. Additionally, pay attention to healthcare policy changes and evolving lifestyle factors, which might impact future mortality rates.
